Concepedia

Kevin Currie

KC

Statistics

Publications

14

Citations

998

H-Index

13

Active since

1995

Affiliations

Gilead Sciences (United States)(Current)

Kevin Currie is an author at Gilead Sciences (United States) specializing in pharmacology, tyrosine kinase inhibitors, and medicine.

ORCID

Publications per year

1995–2021

14

Publications

14

Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis

Julie A. Di Paolo, Tao Huang, Mercedesz Balázs et al. · Nature Chemical Biology · 2010 · 332 citations · Full text

, , +16

Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase

Kevin Currie, Jeffrey E. Kropf, Tony Lee et al. · Journal of Medicinal Chemistry · 2014 · 171 citations · Full text

, , +13

Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton’s Tyrosine Kinase Inhibitor

Lichuan Liu, Jason Halladay, Young G. Shin et al. · Drug Metabolism and Disposition · 2011 · 74 citations

, , +17

Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell–associated damage in IFNα-driven lupus nephritis

Arna Katewa, Yugang Wang, Jason A. Hackney et al. · JCI Insight · 2017 · 72 citations · Full text

, , +17

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

Russell T. Burke, Sarah Meadows, Marc Loriaux et al. · Oncotarget · 2014 · 65 citations · Full text

, , +17

1–5 of 14